author index...subject index i179 carboxylic acids,4-enevpaand4-pentenoic acid,reactivemetabolites,...
TRANSCRIPT
1175
AUTHOR INDEX
Abbott, Frank S., 284, 415, 889,1098
Abdel-Rahman, Mohamed S., 788Abeysinghe, R. D., 640
Abiteboul, Michel, 617Abramson, Fred, 868Adam, Albert, 485Adedoyin, A., 184
Adusumalli, Vidyasagar E., 710,1079
Ahluwalia, Gurpreet, 369, 738Aksoy, I. A., 268
Alberts, David W., 1029Albrecht, E., 818Allievi,C., 151Alton, Kevin B., 198Anders, M. W., 634
Andoh, Katashi, 1142Andrew, P. D., 761Arisen, B. H., 670Aristorena, Juan-Carlos, 215Arvidsson, Annie, 171Au, Jessie L-S., 544
Audibert, 0., 7
Axelson, James E., 284
Babe, Takahiko, 1048Bath, Mostafa Z., 305Bai, Stephen A., 156
Bailey, John R., 364Baillie, Thomas A., 242, 580
Baker, David C., 738Baker,MaxT.,299, 1170Balani, Suresh K., 598Baldew, Glenn S., 30Bandyopadhyay, Abhik M., 782,
1064
Barbhaiya, Rashimi H., 447, 502Barrow,A., 1022Batt, A. M., 939Battagjia,R., 151Bekersky, Ihor, 1017Bend, John R., 334Benedetti, M. Strolin, 151
Benet, Leslie Z., 730Benincosa, Lisa Jo, 750Berger, H., 818Berger, Yves, 978Bernadou,J., 811Bertin, Didier, 1157
Bezek, Stefan, 547Bienvenu, Thierry, 178Biggi, Wendy A., 454
Binienda, Zbigrnew, 364Birch,GaryM., 162
Bishop, Jack B., 1091Bjorge, Susan M., 874
Black,Ann, 1112Blackburn, R. Kevin, 573Bland, T. J., 530Blanz, Joachim, 955
Blom, M., 218Blown, Robert A., 782, 1064
Boeren, Sjef, 508
Boersma, M. G., 218Bogdanffy, Matthew S., 1107Bolton, Mary G., 986Bongard, Robert D., 428Bonnafous, M., 811Bopp, Barbara A., 805
Borel, Anthony G., 415, 889Bouchard, Line, 293Boudinot, F. Douglas, 855Boutin,JeanA., 1157
Bradbury, A., 761Breau,AlanP., 162,249Brendel, Klaus, 454Brenner, Dean E., 277Brett,Claire M., 587
Broder, Samuel, 369Brouwer, Kim L. R., 1129
Burchell, Brian, 50Burka,LeoT.,9l8
Cal, Yong, 605
Canali, Sergio, 144Cano, Jean Paul, 338, 823Cashman, John R., 492, 587, 753Castelli,M.G., 151Castle,M.C., 1147Castonguay, Andre, 293, 318Catalin, Jacques, 338, 823
Chadwick, Majory, 209Championsmith, Antonio, 71
Chan, Tze-Ming, 198Chang, A. S., 125
Chang, Tsun, 874, 1112Chauret, Nathalie, 861, 1029Chay, Sylvia H., 162Chen, 1.-Wu, 800Chen, teng-Man, 480Chenery,R.J., 18Cheng, Xiaoqin, 121Chesa-Jim#{234}nez, Jesus, 215Chiang, Chao-Kuo, 1170
Chiba, Kan, 747Chikai, Toshiyuki, 542Chisena, Christine, 738
Chiu, Shuet-Hing L., 670, 792Cho,A.K., 125
Choi,Y.M.,710
Chou, Chen-Hsi, 933Chow, Fung S.,690
Chu, Chung K., 855ChUi,Y.C., 1119Chung,JungG., 1057
Chung, Suk-Jae, 967
Clarke, S. E., 18
Qement, B�md, 24Cnubben, N. H. P., 218Coddington, Arthur B., 1086
Coe, R. A. J., 1037Colby, Howard D., 200, 1086Colthup, P. V., 1022Colvin, 0. Michael, 986Connors, Suzanne, 454Cook, C. Edgar, 717Cook, Jennifer, 71
Cooney, David A., 369, 738Correia, Maria A., 730Coulombe, Roger A., Jr., 555Cravedi,J.P.,377Cretton, Erika M., 946Cribb, Alastair E., 520
Criscuoli, Marco, 835
Dam, Jeremy 0., 567Daley-Yates, P. T., 100Dalton, James 1., 544Damani, Lyaquatali A., 255
Dandekar, Kishor A., 447
Das, Mukul, 194Davis, Patrick J.,259
Davis, Richard A., 788Dawson, Christopher A., 428Day, Wesley W., 474Debrauwer, L., 377D#{233}chelotte, Pierre, 13
Dedinas, John, 911Defrance,S., 811de Goeij, Jeroen J. M., 30Delaporte, Enock, 520Delous, G., 377DeLuna, Florencia A., 800
De Maack, F., 939Deremer, Susan J., 277DeSante, Karl A., 249
DiLea, C., 662
Dixon, C. M., 761Dogterom, Peter, 699, 705
Donahue, Brian S., 745Dorman, Douglas E., 249Doroudian, Ahmad, 284Doshi, Kokila J.,855
Drerup,J.M., 551Drey,JustinaM., 861, 1029Dubois, Nathalie, 617Duffel, Michael W., 400Duggan, Daniel E., 1003Duhart, Helen M., 364Dumont, Louis, 485Duncan, C. A., 467
Durand, Alain, 338, 823Durham, Sherrie L., 480du Souich, Patrick, 7, 485
Dusterberg, B., 203
Ebner, Thomas, 50Eddy, A. Craig, 309Edwall, BjOm, 171Ehlhardt, William J., 162Ehninger, Gerhard, 955ElDareer,SalahM., 231
Elfarra, Adnan A., 841
Elliott, J. M., 467Ensminger, William D., 277Eugster, Hans-Pietro, 43Evans, Allan M., 933
Fabre, Gerard, 978
Falkner, K. Cameron, 334Farinotti, R., 1125Farooqui, Mohammed Y. H., 460
Faudskar, A. Lawrence, II, 902Favreau, L., 861Feil, V. J.,624
Feng,R., 1119
Fenselau, Catherine, 91 1Ferguson, Nikita I., 745Fernandez, C., 1125
Ferraiolo, Bobbe, 71
Forkert, P. Gek, 770Fornasini, Gianfranco, 933Fournel-Gigleux, Sylvie, 617Franklin, L. Karen, 951Franz, Paula M., 249Fredenburg, Andrea M., 255Fridland, Arnold, 369Friedman, Marvin A., 788
Fu, Emil, 567Fujioka, M., 971Fujita, Shoichi, 1012
Fujitsu,T., 971Fung, Ho-Leung, 967
Gachon, F., 560Gaillard, 0., 560Gandolfi, A. Jay, 386
Garcia-Carbonell, Maria C., 215Gelboin, Harry V., 645Gerig,J.T., 105Geurtsen, Bail, 508Ghanayem, Burhan I., 209Giachetti, Antonio, 835Giacomini, Kathleen M., 587
Gilbert, P. J., 1037Gimenez, F., 1125Gires, P., 997Godeneche, D., 93, 560
Godin, C. 5., 551Goehl, Thomas J., 189God, 0. P., 874Goldberg, Mark J., 249Goldman, Mark E., 598Gomez, Denise Y., 587Gonzalez, Frank J., 1048
Gorski, John, 567Granero, Luis, 215Granneman, G. Richard, 805Griffin, Robert J., 918Grossman, Scott J., 1029Grossman, S. J.,861
Guengerich, F. Peter, 1, 403, 1048
Hackbarth, Ingeborg, 13
Hall, Caroline, 284Hall, Stephen D., 114
Hall,TseW., 133Halpin, Rita A., 1003Hamilton, Robert, 1172
Hanson, Glen, 1017Hao, Zhang, 738Harbison, Raymond D., 537
Harrell, A. W., 18Hartley, T. E., 1037
Hartman, Neil R., 369Hasegawa, Takaaki, 611
Hasinoff, Brian B., 883
1176 AUTHOR INDEX
Hatcher, Barbara L., 249Hebbler, Anna K., 738
Heinrich,N., 811
Hendrickx, Jan, 1134Hennig, Philppe, 1157Herold, E., 861
Herold, Eugene G., 1029
Heykants, Joseph, I 134
Hezari, Mehri, 259Hichens, M., 467Hider, R. C., 640Hider, Robert C., 255Higuchi, Saburo, 524Hill, Donald L., 231
Hill,Judith M., 717Hilibeck, D., 1037Hilton, John, 986Hinderling, P. H., 662Hinton, Melvin L., 62Hiramatsu, M., 125Hirose, Seiyu, 358Hodgson, Ernest, 657Hoffmann, Kurt-Jurgen, 435Hoke, John F., 480Homnick, C. F., 467Horeck�, J., 962Hoyer, G.-A., 203, 682
Hu, Pci, 580Huang, May-Lynn, 1134Huggins, John W., 555
Hwe, J. Michael, 555Hunninghake, Donald B., 1003
Huskey, Su-Er W., 792
Hussein, Ziad, 805Huwe, J. K., 624Hwang, In Young, 841
Inui, Yukihara, 1048Irwin, Richard D., 189Ishii, Itsuko, 358Ishizaki, Takashi, 747Iwakawa, Seigo, 141Iwasaki, K., 971Iyer, Krishna R., 902
Jakobs, U., 203, 682James, Robert C., 537
James, Ruby H., 189
Jarman,M., 1119Jayyosi, Z., 939Jeffcoat, A. Robert, 717
Jenden, D. J., 125Johns, David G., 369, 738Johnson, Norma J., 277Johnson, Robert L., 62Johnston, Michael R., 428Jorquera, Rossana, 318
Joyeux, Henri, 978
Julian, Bernard, 978Jusko, William J., 690
Kathy, Abdelrazak M., 788Kagimoto, Nonko, 1012Kaiser, David G., 951K#{225}llay,Z., 962Kanakubo, Yoshio, 358Kanekal, Sarathchandra, 37Kari, Prasad H., 467, 1003
Kassahun, Kelem, 242, 1098
Kato, Katsuyoshi, 611Kato, Nobuo, 611
Kauffman, Laura. R., 598Kaul, Sanjeev, 447Kehrer, James P., 37Keller, Deborah A., 911Kelley,JamesA., 738Kertscher,U., 818Khanna, Subhash K., 194
Kharasch, Evan D., 350Kim, Myungsoo, 309
Kimura, Toshikiro, 677Kitada, Mitsukazu, 358, 777Kjaassen, Curtis D., 342Knutsen, Conrad A., 277
Kobayashi, Kaoru, 747Komada, Fusao, 141
Komiya, Moriyoshi, 777Kosanke, Stanley D., 605
Kowaluk, Elizabeth A., 967Koziol, T., 662Krause,W., 203,682Krejcy, K., 962Kucharczyk, Norbert, 7 10, 1079Kuhne, G., 682Kukan, Mari#{227}n,547KUlkarni,S., 1022Kunze, Kent L., 350, 874Kupfer, David, 645, 657Kuriya, Shin-Ichiro, 358Kwan, Eddie, 284
Kyerematen, Gabriel A., 927
Labarre, P., 93, 560Lacarelle, Bruno, 338, 823Ladd, David L., 911
Laizure, S. Casey, 951Lake-Bakaar, Desmond, 171
Lambert, Pierre.-Herv#{234}, 1157Lanbeck-Vallen, Kerstin, 171
Landaw, E. M., 125Lankford, Susan M., 156Lapicque, Francoise, 617
Larrauri, Aamparo, 454Larson, Irena W., 200
Le Cotonnec, Jean-Yves, 144Lee,Helen, 1112
Lee, P., 640Lennernas, Hans, 435Levitt, Miriam, 200
Levy,GeraldN., 1057Lewis, Derf, 71
Lewis, Rebecca P., 62Lho#{235}st,G.,850
Lin, Jiunn H., 800Lind, Richard C., 386Linehan, John H., 428Lipa, Joan, 56Lippi, Annalisa, 835Loiseau, P., 811Loizou, George D., 634
Lonning, P. E., 1119Los, Gerrit, 30Los, Layne E., 1086Lustig, Kiemens L., 24
Maconochie, J. G., 1022Madelmont, J. C., 93, 560
Madhu, Cherukury, 342
Magdalou, Jacques, 617Manabe, Kyoko, 747Manchee, G. R., 1022Mani, Chitra, 645, 657Mams, Melanie, 181Mannens, Geret, 1134
Mantlo, N. B., 670Maradeix,V., 1125
Marathe, P. H., 502
Markham, Peter M., 209
Marshall, M. L., 640Martdll, Karen J., 965Martin, Ulrich, 236Martinet, M., 997Maskasame, Chaiyasit, 156Mason, William D., 305Masubuchi, Yasuhiro, 1012Mather, Laurence E., 1151Maton, N., 850Matsubara, Takashi, 542Mattiuz, Edward L., 249
Maurice, Marie-Helene, 617Mayersohn, Michael, 1091, 1172McCague,R., 1119McCallum, Gordon P., 334
McClain,CraigJ., 1064
McClure, Harold M., 855McLean,ColinF., 1151
McNally, William, 1 1 12
McVie, J. Gordon, 30Melus, Mikul#{225}s,547
Mengozzi, Grazia, 835Meuldermans, Willem, 1134
Meunier, B., 8 1 1Meunier, Florent, 1157Miller, Mario, 951
Miller, Randall R., 670, 792Millington, G., 662Milne, Robert W., I151
Mimura, Mayumi, 1048
Mitchell, David Y., 342, 396Mitsuya, HirOaki, 369Mohammed, N., 640Mohler, Maijorie, 71
Mong, Seymour, 1017Moore, Jerome, 71Mordenti, Joyce, 71
Moreau, M. F., 93, 560Morgan, Edward T., 745
Morris, Marilyn E., 750Mousse, Madeleine, 770Muindi, J. F., 410Mulder,GerardJ., 1070Mulford, Darcy I., 805Murphey, Lame J., 390Murphy, Constance M., 911Musser, Steven M., 738
Nabeshima, Toshitaka, 611Nadai, Masayuki, 611Nagase, K., 971
Nakano, Masyuki, 542Nakasa, Hiromitsu, 777Nakatsuka, Iwao, 1167
Narimatsu, Shozuo, 1012Nation, Roger L., I 151Nelson, Wendel L., 309
Netter, Patrick, 617
Nicoletti, Joseph, 567Nicoll-Griffith, Deborah A., 861,
1029Nijmeijer, Sandra M., 441
Noda, K., 971Noe, Dennis A., 986Nomeir, Amin A., 209Noordhoek, Jan, 441
O’Brien, Julie A., 598Occolowitz, John L., 249Oehlke, J., 818Ohmori, Shigeru, 358, 777, 1048Ohnishi, Noriaki, 141
Okereke, Chukwuemeka S., 788Okerholm, Richard A., 403Okumura, Katsuhiko, 141Olah, Timothy V., 598Olive, Georges, 178Olsen, George D., 390Olsen, Mark A., 911
Ong, Huy, 485
Otterness, D. M., 268Ottoila, Pekka, 81Oxford, J., 761, 1022
Page, John G., 189Palmer, B. D., 530Palmer, E., 1022Pang, K. Sandy, 1070Papon,J.,93,560
Park, Sang B., 587Park, Sang S., 645Parkinson, Andrew, 645Patel, Dipak K., 62Patetta, Patricia K., 717
Patrick, Darryl H., 1029Paule, Merle G., 364
Paulson, G. B., 624Paxton, J. W., 530Pearce, Robin, 645Pennick, M., 18Perez-Reyes, Mario, 717Peris-Ribera, Jos#{233}-Esteban, 215Perno, Carlo-Federico, 738Perreault, Sylvie, 485Perry, P. R., 184Petersen, Dennis R., 396Piatkowski, T. S.,474
Piekoszewski, Wojiech, 690
Piotrovskij, V. K., 962Piper, John, 460Pittman, K. A., 502Pitzenberger, Steven M., 467, 598Pl#{225}-Delfina,Jos#{233}M., 215
Podoll, Terry, 350Pongchaidecha, M., 100
Pons, Gerard, 178Pool, William F., 874Poon,G.K., 1119Porchet, Herv#{233}C., 144
Porter, J. B., 640Posey, Claude F., 231Pramanik, Birendra, 198Prejean,J. David, 189Pritchard, Mike, 617Probst, Markus, 43Prome, D., 377Pmeksaritanont, Thomayant, 730
AUTHOR INDEX 1177
Pugh, Dorothy E., 717
Puhl, R. James, 1017
Purchase, Claude F., II, 874
Quijano, Romeo F., 141
Raberger, G., 962Rajaonarison, Jean-Francois, 338,
823Ramamurthy, S., 125Ramjit, Ham G., 598, 1086Rapp, M., 93Redureau, M., 997Reg#{227}rdh,Carl-Gunnar, 435Remmel, Rory P., 902Renberg, Lars, 435Renner, Ulf, 955
Renton, Keeneth W., 520Rettie, Allan E., 730Rey, Elisabeth, 178
Rietjens, Ivonne M. C. M., 218,508
Rikans, Lore E., 605
Rikihisa, Tadaaki, 358, 777Roberts, Eve A., 56Roberts, Stephen M., 537Robertson, I. G. C., 530Robertson, Keith D., 986Robertson, LaiTy W., 782
Roerig, David L., 428Romanyshyn, L. A., 710Ronnenberg, William C., Jr., 1170Rooney, Clarence S., 598Rose, Lucy M., 231Rosegay,A., 670Rosenberg, Daniel W., 846Rothuizen, Jan, 705Rowland, Malcolm, 933Rowlands,M.G., 1119
Rubin, Alan, 249Runciman, William B., 1151Rurak, Dan W., 284Ruth, James A., 121
Rutten, Albert J., 1151Ruzicka,JanA., 1170
Sabouraud. Alain, 13, 997
Sadler, Brian M., 717Saint-Aubert, Bernard, 978Sakuma, S., 971Sandberg, Jennifer, A., 390Sanders, Paula L., 951Sandouk, Pierre, 13Sandow,J., 811
Sardelli, Giuliana, 835Sato, A., 971Saumer, C. G., 7Sawamoto, Taiji, 677Saynor, D. A., 761Scallen, Terence J., 567Scherrmann, J. M., 997Schey, K. L., 76Schinazi, Raymond F., 855Schmeer, Karl, 955
Schmid, Christopher R., 249Schmitz,DebraA., 125
Schorn, Terry. W., 598Schroeder, David H., 62Schroeder, Mel C., 874Schuller, Hildegard M., 318
Schwenk, Michael, 13Seaton, Mark J., 927Sengstag, Christian, 43Serkiz, Bernard, 1 157
Sharma, Raghubir P., 555Shear, Neil H., 830Shedlofsky, Steven I., 1064Shen, Danny D., 309Shimada, Tsutomu, 1048
Shimatani, K., 971Shipley, Lisa A., 753
Shiraga, T., 971
Shirley, Michael A., 580Shockcor, John P., 62
Shono, Fumiaki, 1167Shukla, Umesh A., 447, 502Shum,Y.Y., 1112
Shyu, Wen C., 447Siest, Gerard, 617, 939Sigel, Carl W., 62
Singh, S., 640
Sinicropi, Dominick, 71Sipes, I. Glenn, 1091
Skinner, Thomas L., 255Slikker, Jr., William, 364Sloan,PaulA., 1151
Smith, David E., 277Smith, D. J., 624Smith, J. L., 670Smith, Steven J., 598Snel, C. A. Wilco, 1070Sofia, R. Duane, 710, 1079Sommadossi, Jean-Pierre, 946Somogyi,AndrewA., 1151Song, Hengchang, 868Soria, Imaculada, 724Sparadoski, R. E., Jr., 710Sponer, Gisbert, 236
Stearns, R. A., 670
Stetson, PhilipL.,277Stevens, Jeffry C., 753Stevens, Robert C., 951Stevens, Yee-Wan, 410Stiller, Steven W., 231
Stowe, Emily E., 738
Streeper, Robert T., 986Strein, Klaus, 236Struck, Robert F., 231Subissi, Alessandro, 835Suzuki, Akira, 677Suzuki, Tokuji, 1012Swinney, David C., 730Sylvia, L. A., 105
Tabuchi, Takeo, 1142
Tanaka, Yoshio, 677
Tandon, Sangita, 194
Tani, Masayoshi, 747Tamguchi, Tomoyoshi, 358Tarbit, M. H., 761, 1022
Taskinen, Jyrki, 81, 325Taylor, Marie L., 1107Taylor, Wesley G., 133
Tenney, Kirsten A., 745Teramura, Toshio, 524Terrio, Patricia A., 277Theoharides, Anthony D., 598Thiroux, Genevieve, 178Thomas, Paul E., 730, 939Thomassin, J., 151Thornburg, K. R., 76
Thuillier,A., 1125Thummel, Kenneth E., 350Till,AliceE., 1003
Tillery, Kathleen F., 231
Tinker, John H., 1170Toler, Steven M., 1064
Torres-Molina, Francisca, 215Tozuka, Z., 971Tracy, Timothy S., 114Trager, William F., 874Trang, John M., 189
Trimble, L. A., 861Trnovec, T., 962
Troke, J. A., 1037Turcan, R. G., 1037Tyrakowska, Bozena, 508
Uchida, Taisuke, 524
Uetrecht, Jack P., 830Ulm,EdgarH., 1003Umbenhauer, Diane R., 1029Umeda, Kayo, 141Usui, Takashi, 524
van Berkel, W. J. H., 218Van Breemen, Richard B., 573VandenBranden, Mark, 753Van Miert, Adelbert S. J. P. A. M.,
441Varga, Sandor L., 598
Vedres, Darrell D., 133Venkataraman, Pankaja S., 605Verbeeck, R. K., 850Vermeulen, Nico P. E., 30
Vervoort, J., 218Vesell, Elliot S., 927Vestling,MarthaM.,9ll
Veyre, A., 93,560Vickers, Alison E. M., 454
Vickers, S., 467Vidal,M.,8l1
Vilhiere, Valerie, 485Villoutreix, J., 939Vinegar,A., 551
Vogelaar, John P. W., 454Voice, Ronald A., 181
Volland, Jean-Paul, I 157Vose,C.W., 1037
Vuorela, Aija, 81
Vyas. Kamleash P., 1003
Vyas, K. P., 467
Walle, T., 76
Walle, U. K., 76
Walters, Karen M., 305
Wang, Li, 611Wang, Ying, 299Warrell, Raymond P., Jr., 410Washington, Carla B., 587Watanabe, Takashi, 524
Weber, Wendell W., 181, 965,
1057Wedlund, Peter J., 255Weiner, Myron, 474Weinshilboum, R. M., 268
Wheeler, S. M., 18Wheeler, William J., 162White, W. Reid, 717Wichmann, Joseph K., 710, 1079Wikberg, Tom, 8 1, 325Wilkinson, G. R., 184Williams, Cheri L., 951Williams, Theresa M., 598Winter, Steven M., 1091Wirthwein, Darren P., 114Witkamp, Robert F., 441Woestenborghs, Robert, 1134Wong, K. K., 710
Woolf, Thomas F., 547, 874, 1112Wrighton, Steven A., 492, 753W#{252}rgler,Friederich E., 43
Xie, Zhang, W., 56
Yabuki, Masashi, I 167
Yamazaki, Hiroshi, 1048Yang, Lihong, 492Yang, Suyun, 56Yang, Zi-Chen, 587Yang, Zicheng, 492Yarchoan, Robert, 369Ybarra, Benjamin, 460
Yeleswaram, Krishnaswamy, 284Yergey, James A., 86 1, 1029Yisak, Wolde, 171Yorkel, Robert A., 255Yoshida, Toshiaki, 1142Yoshitake, Akira, 1167Young, A. Bryon, 1064Young, Charles W., 410Yun, Chul-Ho, 403Yun, Hyoin, 441
Zahid, Nasir, 830ZaInbOni, R., 861Zannikos, Peter N., 782
Zanolo, Giovanni, 144Zeller, Klaus-Peter, 955Zhao, Ying, 1070
Zheng, Wei, 1091Zheng, Yuqun, 400Ziegler, Daniel M., 24Ziegler, J. M., 939Zimmerman, Cheryl L., 724,902
Zollinger, Markus, 454
1178
SUBJECT INDEX
Acetaminophen, disposition of metabolites, acute phenobarbital admin-istration (rats), 1129
Acetyl coenzyme A-cholesterol acyltransferase inhibitor, metabolic N-demethylation (rats), 524
N-Acetyltransferasep-aminobenzoic acid, distribution of 2-aminofluorene, tissues of rapid
and slow acetylators (mice), 1057red blood cell, inhibition of(humans), 181
Acridine carboxamide, metabolism (mice), 530
Acyl-coenzyme A:cholesterol acyltransferase, inhibitor 2,2-dimethyl-N-
(2,4,6-thmethoxyphenyl)dodecanamide, biodisposition studies
(rats,monkeys), I 112Adrenal gland, microsomal monooxygenases, zonal differences, thermal
lability (guinea pigs), 200Aging, redox cycling and hepatotoxicity (rats), 605Albuterol, stereoselective sulfation (humans), 76
Aldehyde dehydrogenases, liver mitochondrial and cytosolic, inhibitionby crotonaldehyde (rats),396
Alendronate, uptake by bone tissue, hypocalcemia and hypercalcemia(rats), 800
Allylnitrile, toxicokinetics (rats), 460Amines, tertiary, stereo- and regioselective N- and S-oxidation, liver
microsomes (humans), 492p-Aminobenzoic acid, N-acetyltransferase activity in tissues, distribution,
rapid and slow acetylators (mice), 10572-Aminofluorene, p-aminobenzoic acid N-acetyltransferase activity and,
tissues, C57BL/6J rapid and B6.A-Nai’ slow acetylator congenicmice, 1057
3-Amino-l-phenylbutane, disposition and metabolism, pharmacody-namics oflabetalol (sheep), 284
Amiodarone, CYP3A-mediated N-deethylation, liver microsomal frac-
tions (humans), 978Androgens, biotransformation and branchial excretion, 17a-methyltes-
tosterone (fish), 377Anesthetics, halothane biotransformation, concentration-dependent in-
hibition (guinea pigs), 386Antianxiety agents, zatosetron disposition (humans), 249Antiarrhythmic agents, class III, metabolism studies (dogs), 467
Antibiotics, cefadroxil, nonlinear pharmacokinetics (rats), 215Anticancer drugs, glucuromdation of 3’-azido-3’-deoxythymidine, liver
microsomes (humans), 823Anticonvulsants, felbamate, distribution to cerebrospinal fluid and brain
(rats),1079
Antidepressants, DL-rolipram, biotransformation, metabolites from wine(rats, monkeys, humans), 682
Antiinfective agents, 1,3-di(4-imidazolino-2-methoxyphenoxy)propane,
disposition (rats), 1017Antiviral agents
carbocycic 3-deazaadenosine pharmacokinetics (mice), 555l,3,4-thiadiazol-2-ylcyanamide, biotransformation (mice), 162
Argemone, alkaloid sanguinarine, biometabolic elimination, organ reten-tion profile (rats, guinea pigs), 194
Arsenite, effect on NAD(P)H:quinone acceptor oxidoreductase activity,
liver and lung, heart and kidney (rats), 334
Aryl sulfotransferaselV, hepatic, naphthaldehydesas reversible inhibitors(rats),400
Assays
immobilized digestive enzyme, chemical and enzymatic hydrolysis,
lysobactin, 573simplified methodology for quantitation, butadiene metabolites (rats),
121Atropine, gastrointestinal motility, bioavailability of cyclosporine A
(rats),141
3’-Azido-2’,3’-dideoxy-5-methylcytidine, pharmacokinetics and metab-olism (monkeys), 855
3’-Azido-2’,3’-dideoxynucleosides, reduction to 3’-amino metabolite,cytochrome P-450 and NADPH-cytochrome P-450 reductase,
liver microsomes (rats), 9463’-Azido-3’-deoxythymidine, glucuronithtion, effect of anticancer drugs,
liver microsomes (humans), 823
Barbiturates, homologous series, lipophilicity and hepatic dispersion,liver(rats),933
l,5-Benzodiazepine, metabolic profiling ofclobazam (rats), 415Benzophenone-3, metabolism (rats), 788Benzoylecgonine, metabolism of cocaine, inhibition by ethanol (mice,
humans), 537Bernard B. Brodie Award, bioactivation and detoxification, toxic and
carcinogenic chemicals, 1Biantrazole, detection and identification, urinary metabolites (humans),
955Bile
excretion ofglutathione and hydrolysis products, P-450 inducers (rats),342
glucuronidation as transient intermediate metabolic step, eliminationofcarbovir (rats), 902
rates of excretion, cotinine, nicotine glucuronide and 3-hydroxycotin-inc (rats), 927
1,2-Bis(2,4,6-tribromophenoxy)ethane, disposition following administra-
tion in diet (rats), 2091,3-Bis[[1-cycloheptyl-3-(P-d.imethylaminophenyl)ureido)methyl)ben-
zene dihydrochlonde, metabolic N-demethylation (rats), 524Bisphosphonates, pamidronate, 4-hour and 24-hour infusions, clearance
and tissue uptake (rats), 100
�3-Blockers, pafenolol, pharmacokinetics and metabolism (rats, humans),435
BM 006.022, pharmacokinetic properties, influence, hepatic and renalfailure (rats), 236
Bone, uptake of alendronate, hypocalcemia and hypercalcemia (rats),800
Brain
distribution of felbamate (rats), 1079tirilazad disposition (rats), 951
Breast neoplasms, phase I and phase II metabolites, tamoxifen (humans),1119
Bromodeoxyuridine, 5-fluorouracil or iododeoxyuridine, mutual kineticinteraction (dogs), 277
Bromosulfophthalein, localization of glutathione conjugation activities,perfused liver (rats), 1070
Bronchodilators, salmeterol xinafoate, disposition (rats, humans), 1022Buserelin, disposition (rats), 818Butadiene, metabolites, methodology for quantitation, liver microsomes
(rats),121
Caffeineestradiol and progesterone, interaction with CYP1AI and CYP1A2,
Saccharomyces cerevisiae (human), 43metabolism in liver slices, postnatal development (rats), 178
Calcium, antagonist SM-6586, cleavage, 1,2,4-oxadiazole ring, 11673-Carbamoyloxy-2-phenylpropionic acid, major urinary metabolite of
felbamate (humans), 710Carbocycic 3-deazaadenosine, pharmacokinetics (mice), 555Carbovw
disposition in the in situ perfused liver, intestinal vasculature prepa-rations (rats), 724
glucuromdation, transient metabolic step (rats), 902Carboxylesterase-mediated metabolism of vinyl acetate, kinetics (rats),
1107
SUBJECT INDEX I 179
Carboxylic acids, 4-ene VPA and 4-pentenoic acid, reactive metabolites,thiol conjugates, 1098
Carcinogenscharacterization of cytochrome P-450 2B6, liver microsomes (hu-
mans), 1048metabolism of�methylnitrosamino�1-(3-pyridyl)-l-butanone, inhib-
itory effects ofNSAIDs, lung explants (mice), 293toxic and carcinogenic chemicals, bioactivation and detoxification, 1
Catalysts, oxidative drug metabolism studies, model systems, 811Catechol-O-methyltransferase
inhibitor entacapone, major metabolites (rats, humans), 81inhibitor nitecapone, major metabolites (rats, dogs), 325
Cefadroxil, nonlinear pharmacokinetics (rats), 215Cefcanel daloxate hydrochloride, disposition (humans), 171Cerebrospinal fluid, distribution of felbamate (rats), 1079Chinese hamster ovary cells, pharmacokinetics, recombinant human
follicle-stimulating hormone (monkeys), 1442-Chloro-l,l-difluoroethene, isoflurane-facilitated metabolism, NADPH
and oxygen consumption, liver microsomes (rabbits), 299l-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, metabolites, carbamoy-
lated thiol conjugates (rats, humans), 8892-(Chloroethyl) nitrosoureas
cysteamine-containing, main urinary metabolites (rats, humans), 93orally administered mitozolomide, biodistribution and metabolism
(mice), 560p-Chloronitrobenzene, pharmacokinetic study, acute poisoning (hu-
mans), 1142
5-Chloro-3-phenylthioindole-2-carboxamide, biotransformation, potent
HIV-1 reverse transcriptase inhibitor (monkeys, rats), 598
Cholesterol, sulfation in liver (humans), 268
Cholesterol acyltransferase, metabolic N-demethylation, l,3-bis[[l-cyclo-heptyl-3-(p-dimethylaminophenyl)ureido] methyl)benzene dihy-drochloride (rats), 524
CI-976, biodisposition studies (rats, monkeys), 1112CI-941, see BiantrazoleCigarette smoking, S-methamphetamine hydrochloride, pharmacoki-
netics (humans), 717Cimetidine
chemical, enzymatic, and enantioselective S-oxygenation (humans),587
inflammation and hypoxia, propofol kinetics (rabbits), 7
Cisplatin, reduction of nephrotoxicity, sodium selenite (mice, rats), 30Clarithromycin, mixed function oxidase system, hepatic microsomes
(rats), 358Qot,a.�am, metabolic profiling (rats), 415Cobalt chloride, cobalt-protoporphyrin and, pharmacokinetics(rats), 846Cocaine
hepatic biotransformation (guinea pigs), 390inhibition ofmetabolism, benzoylecgomne and ecgonine methyl ester,
liver (mice, humans), 537maternal/fetal plasma concentrations, transplacental pharmacoki-
netics (monkeys), 364Coenzyme A, metabolic inversion of(R)-ibuprofen (rats, humans), 114
Colchicine-speciflc Fab fragments, hepatic clearance (rats), 997Colon, morphine uptake, 3- and 6-glucuronidation (guinea pigs), 13Compartments, multicompartment model, terminal disposition half-life,
mean residence time, 1172Cotinine, rate of excretion in bile (rats), 927CQA 206-291, biotransformation, plasma clearance (humans, dogs,
rats), 454Crotonaldehyde, inhibition, liver mitochondrial and cytosolic aldehyde
dehydrogenases (rats), 396Cunninghamella degans, microbial models of mammalian metabolism,
formation of furosemide glucoside, 259Cyclophosphamide, peroxidase-mediated metabolism (mice), 37Cyclosporine, metabolism by liver microsomes (rats), 730Cyclosporine A, bioavailability, effect ofatropine, gastrointestinal motH-
ity(rats), 141
CYP1A1, specificity of verlukast epoxidation (mice, rats, monkeys, hu-mans), 1029
CYP2B, induction of enzymes, nutritional obesity, phenobarbital treat-
ment (rats), 782CYP3A-mediated N-deethylation of amiodarone, liver microsomal frac-
tions (humans), 978CYP3A1, modulation of induction, polyinosinic acid-polycytidylic acid
(rats),520
CYP4A, subfamily gene products, pretranslational induction, reversal byoral vanadate treatment (rats), 745
Cysteamine-containing 2-(chloroethyl) nitrosoureas, main urinary me-
tabolites (rats, humans), 93
Cytochrome P-450lA family, inducibility ofenzyme activities, hepatocytes (human), 562B6, characterization, liver microsomes (humans), 1048bioactivation and detoxification, toxic and carcinogenic chemicals, 1
-catalyzed N-demethylation and 4-hydroxylation, tamoxifen metabo-lism (rats), 645
enzymes and head injury (rats), 1064flavin-containing monooxygenase and, biotransformation, 4-fluoro-N-
methylaniline, 218
inducers, biliary excretion of glutathione, hydrolysis products (rats),342
isozymes, hydroxylation ofdantrolene, liver microsomes (rats), 939liver microsomal, reductive metabolism, zonisamide (rats), 777-mediated dehydrogenation, 2-n-propyl-2(E)-pentenoic acid, liver mi-
crosomes (rats), 242metabolic N-demethylation, l,3-bis[[l-cycloheptyl-3-(p-dimethylami-
nophenyl)ureido) methyl)benzene dihydrochloride (rats), 524NADPH-cytochrome P-450 reductase and, reduction of 3’-azido-2’,
3’�deoxynucleosides, liver microsomes (rats), 946
regioselective contribution of 2D subfamily, propranolol metabolism,liver microsomes (rats), 1012
sex hormone-dependent, sulfamethazine as a model compound (rats),441
Cytochrome P-450 2El, liver microsomal enflurane defluorination (rats),350
Cytochrome P-450 3A4, oxidation ofterfenadine, liver microsomes (hu-mans), 403
Cytosol, aldehyde dehydrogenases, liver mitochondria, inhibition by
crotonaldehyde (rats), 396
Dantrolene, hydroxylation, cytrochrome P.450 i�ozymes, liver micro-
somes (rats), 939Dapsone
inhibition of red blood cell N-acetyltransferase (humans), 181sulfamethoxazole and, N-chlorination, myeloperoxidase system, 830
Dehydroepiandrosterone sulfotransferase, cholesterol sulfation in liver(humans), 268
Deoxyribonuclease, recombinant human, altered pharmacokinetics,presence ofbinding protein (rats), 71
Desferrioxamine, intravenous infusion pharmacokinetics, thalassemia(humans), 640
Desmethyipromethazine, oxidation, liver flavin-containing monooxy-genase (pigs), 24
Deuterium, substitution, inhibitory effects, sevoflurane metabolism
(rats), 1170Diabetes
pharmacokinetics of zenarestat (rats), 677pretranslational induction, CYP4A subfamily gene products, reversal
by oral vanadate treatment (rats), 7452,2-Dichloro-l,l,1-thfluorethane, liver microsomal metabolism (rats),
551l,l-Dichloroethylene, temporal effects, nonprotein sulfbydryl content,
lung and liver (mice), 7701,l-Dichloro-l-fluoroethane, gas-uptake pharmacokinetics, biotransfor-
mation (rats), 634Didanosine, absorption, disposition and metabolism (dogs), 447
1180 SUBJECT INDEX
2 ‘ ,3 ‘-Dideoxyadenosine-5 ‘-triphosphate, anomalous accumulation and
decay, 2’,3’-dideoxyinosine exposure, T-cell cultures (humans),369
2’,3’-Dideoxycytidine diphosphocholine, 2’,3’-dideoxycytidine diphos-
phoethanolamine and, characterization, 7382’,3’-Dideoxyinosine
anomalous accumulation and decay, 2 ‘ ,3 ‘-dideoxyadenosine-S ‘-#{252}i-phosphate, T-cell cultures (humans), 369
no metabolism in placenta (humans), 544N,N-Diethylbenzamide, N,N-diethyl-a,a’-’3C-benzamide and, metabo-
lism by liver microsomes (rats), 133
Digestive enzymes, immobilized, application of assay, chemical and
enzymatic hydrolysis oflysobactin, 573
Digitoxigenin monodigitoxoside, UDP-glucuronsyltransferase activity,liver microsomes (humans), 338
Digitoxin, �-glucuronidase-resistant glucuronide conjugate, liver micro-
somes (dogs), 11475,6-Dihydro-7-( lH-imidazol-l-yl)-naphthalene-2-carboxylic acid, in vivo
glucuronidation (rats, humans), 151Dihydropyndine, calcium antagonist SM-6586, cleavage, 1,2,4-oxadi-
azolering, 1167
Dihydropyrimidine amidohydrolase, enzymatic ring-opening reactions,ICRF-187 and ICRF-l86, 883
l,3-Di(4-imidazolino-2-methoxyphenoxy)propane, disposition (rats),
1017Diltiazem, disposition and negative dromotropic activity, effects of pro-
pranolol, multiple dosing (dogs), 156Dimenhydrinate, disposition of, effect of propylene glycol (rabbits), 3051,2-Dimethyl-3-hydroxypyridin-4-one, pharmacokinetics (rabbits), 255
2,2-Dimethyl-N-(2,4,6-trimethoxyphenyl)dodecanamide, biodispositionstudies (rats, monkeys), 1112
Diosmetin, glucuronidation (rats), 1157Diquat, redox cycling and hepatotoxicity, aging (rats), 605Ditekiren, hepatic elimination (rats), 184DN-2327, see Pazinaclone
DNA, intercalator 502U83, pharmacokinetics and disposition (rats), 62DNA, complementary, Saccharomyces cerevisiae, interaction with
CYPIA1 and CYPIA2, caffeine/estradiol/progesterone (human),43
DNA adducts, bioactivation and detoxification, toxic and carcinogenicchemicals, 1
Doxorubicin, uptake in lungs, influence, temperature and plasma protein
(rabbits), 428Dramamine, disposition of, effect of propylene glycol (rabbits), 305
Ecgonine methyl ester, metabolism of cocaine, inhibition by ethanol(mice, humans), 537
Endonucleases, altered pharmacokinetics, recombinant human deoxyri-
bonuclease, presence of binding protein (rats), 71Endotoxemia, bacterial lipopolysaccharide, disposition and renal hand-
ling, enprofylline (rats), 611Enflurane, defluorination, cytochrome P-450 2E1 as major catalyst, liver
microsomes (rats), 350Enprofylline, disposition and renal handling, bacterial lipopolysaccha-
ride, endotoxemia (rats), 611Entacapone, catechol-O-methyltransferase inhibitor, major metabolites
(rats, humans), 81Enzymes
hepatic drug metabolism, comparison, Phases I and II (humans, mon-keys), 753
other than cytochrome P-450 3A, cyclosporine metabolism, livermicrosomes (rats), 730
Epoxide, isomerized metabolite of FK-506, erythromycin-induced livermicrosomes (rabbits), 850
Ergot, derivative CQA 206-291, biotransformation, plasma clearance(humans, dogs, rats), 454
Erythromycin-induced liver microsomes, isomerized epoxide metabolite,FK-506 (rabbits), 850
Estradiol, caffeine and progesterone, interaction with CYP1A1 and
CYP1A2, Saccharomyces cerevisiae (human), 43Ethanol, inhibition of cocaine metabolism, benzoylecgonine and ecgon-
inc methyl ester, liver (mice, humans), 537Ethimizol, xanthine-related, nonlinear elimination, 3-methylcholan-
threne-induced liver (rats), 547Ethoxyresorufin O-dethylase, inducibility of enzyme activities, cyto-
chrome P-450 lA family, hepatocytes (human), 56Exercise, treadmill, increased renal drug metabolism, Fischer-344 male
rats,474
Fab fragments, colchicine-specific, hepatic clearance (rats), 997
Famiciclovir, 6$-hydroxylation of testosterone, liver microsomes (hu-mans), 18
Fatty acids, metabolic inversion of (R)-ibuprofen, formation, ibupro-fenyl-coenzyme A (rats, humans), 114
FCE 22 178, 5,6-dihydro-7-( 1H-imidazol- l-yl)-naphthalene-2-carboxylicacid, in vivo glucuronidation (rats, humans), 151
Felbamatedistribution to cerebrospinal fluid and and brain (rats), 1079major urinary metabolite, 3-carbamoyloxy-2-phenylpropionic acid
(humans), 710Fetus
hepatic biotransformation ofcocaine (guinea pigs), 390
maternal/fetal plasma concentrations of cocaine, transplacental phar-macokinetics (monkeys), 364
FK 506
disposition, role of red blood cell binding, hepatic clearance (rabbits),
690isomerized epoxide metabolite, erythromycin-induced liver micro-
somes (rabbits), 850oxidative metabolites (rats), 971
Flame retardant, l,2-bis(2,4,6-tribromophenoxy)ethane, disposition fol-lowing administration in diet (rats), 209
Flavin
-containing monooxygenasecytochromes P-450 and, biotransformation of 4-fluoro-N-methylan-
iline, 218enantioselective S-oxygenation, cimetidine (humans), 587N-oxidation, tamoxifen metabolism (rats), 657
oxidation ofdesmethylpromethazine (pigs), 24Flavoenzymes, microsomal, xanthine oxidase and, differential metabo-
lism of merbazone (rats), 410Flavonoids, diosmetin, glucuronidation (rats), 1157Flumecinol, metabolism, fluorine NMR studies (rats), 105Fluorine, NMR studies, metabolism offlumecinol (rats), 1054-Fluoro-N-methylaniline, biotransformation, role of cytochromes P-
450, flavin-containing monooxygenase, 2185-Fluorouracil, bromodeoxyuridine or iododeoxyuridine, mutual kinetic
interaction (dogs), 277Fluvastatin sodium, biotransformation (humans), 567Follicle-stimulating hormone, recombinant human, pharmacokinetics
(monkeys), 144Furosemide glucoside, formation, microbial models, mammalian metab-
olism, 259
Gastrointestinal tract
effect of atropine on motility, bioavailability of cyclosporine A (rats),141
morphine uptake, 3- and 6-glucuronithtion (guinea pigs), 13Gene, UGT1, substrate specificities, liver UDP-glucuronosyltransferases,
50fl-Glucuronidase
in vivo glucuronidation, 5,6-dihydro-7-(1H-imidazol-l-yl)-naphtha-lene-2-carboxylic acid (rats, humans), 151
-resistant glucuronide conjugate ofdigitoxin, liver microsomes (dogs),1147
‘y-Glutamyltranspeptidase, glutathione and hydrolysis products, biliaryexcretion, effect of P-450 inducers (rats), 342
SUBJECT INDEX 1181
Glutathione
conjugation activities toward bromosulfophthalein, perfused liver
(rats), 1070hydrolysis products and, biliary excretion, effect of P-450 inducers
(rats), 342reaction of meiphalan, kinetic analysis (humans), 986
Glycoaldehyde, metabolism by liver microsomes, N,N-diethyl-a,a’-’3C-benzamide, N,N-diethylbenzamide (rats), 133
Gonadotropin-releasing hormone, 3H-labeled, disposition, buserelin
(rats), 818
Guengerich, F. Peter, 1992 Bernard B. Brodie Award Lecture, bioacti-vation and detoxification, toxic and carcinogenic chemicals, 1
Gut, disposition of morphine, 3- and 6-glucuronide metabolites (sheep),1151
Halothane, biotransformation, concentration-dependent inhibition
(guinea pigs), 386Head, injury, cytochrome P-450 enzymes (rats), 1064Heart
arsenite effects, NAD(P)H:quinone acceptor oxidoreductase (rats), 334tirilazad disposition (rats), 951
Hepatocytesinducibility of enzyme activities, cytochrome P-450 1A family (hu-
man), 56
stereochemical studies, fl-oxidation, valproic acid (rats), 580Hepatotoxicity, redox cycling and, diquat, aging (rats), 605Hep G2 cells, stereoselective sulfation of albuterol (humans), 76Histamine, oxidation ofterfenadine, liver microsomes (humans), 403
Human immunodeficiency virus2’,3’-dideoxycytidine diphosphocholine, 2’,3’-dideoxycytidine di-
phosphoethanolamine, characterization, 7382’,3’-dideoxyinosine exposure of T-cells, anomalous accumulation
and decay, 2’,3’-dideoxyadenosine-5’-triphosphate (humans),
369Human immunodeficiency virus-l
metabolism and disposition, thiazolobenzimidazole (mice), 231reverse transcriptase inhibitor, biotransformation, 5-chloro-3-phenyl-
thioindole-2-carboxamide (monkeys, rats), 598Hydrocarbons, polyaromatic, arsenite effects, NAD(P)H:quinone accep-
tor oxidoreductase activity, various organs (rats), 3343-Hydroxycotinine glucuronide, rate ofexcretion in bile (rats), 927
3-Hydroxypyridin-4-ones, pharmacokinetics (rabbits), 255
Hypocalcemia, hypercalcemia and, uptake of alendronate, bone tissue
(rats),800
Hypouricemi� . differential metabolism of merbazone, xanthine oxidase,
microsomal flavoenzymes (rats), 410
Hypoxia, cimetidine and inflammation, propofol kinetics (rabbits), 7
(R)-Ibuprofen, metabolic inversion, formation of ibuprofenyl-coenzymeA (rats, humans), 114
Ibuprofenyl-coenzyme A, formation, metabolic inversion of(R)-ibupro-fen (rats, humans), 114
ICRF-187, ICRF-186 and, enzymatic ring-opening reactions, dihydro-
pyrimidine amidohydrolase, 883Idapril, pharmacokinetics and pharmacodynamics (rats, dogs, humans),
835Incubation system, metabolism studies, precision-cut liver slices (rats),
699
Inflammation, cimetidine and kinetics, propofol kinetics (rabbits), 7
Interferon, inducer polyinosinic acid-polycytidylic acid, modulation, he-
patic CYP3A1 induction (rats), 520Intestine
morphine uptake, 3- and 6-glucuromdation (guinea pigs), 13vasculature preparations, carbovir disposition (rats), 724
Iododeoxyuridine, 5-fluorouracil and bromodeoxyuridine, mutual ki-netic interaction (dogs), 277
Iron chelators, pharmacokinetics of 3-hydroxypyridin-4-ones (rabbits),255
Isoflurane-facilitated 2-chloro-1,l-difluoroethene metabolism, NADPHand oxygen consumption, liver microsomes (rabbits), 299
Ketoprofen glucuronide, in vitro irreversible binding, plasma proteins
(rats), 617Kidney
arsenite effects, NAD(P)H:quinone acceptor oxidoreductase (rats), 334diposition and handling of enprofylline, bacterial lipopolysaccharide,
endotoxemia (rats), 61 1failure, pharmacokinetic properties, BM 06.022 (rats), 236increased drug metabolism, treadmill-exercised Fischer-344 male rats,
474
membrane vesicle preparations, inhibition ofsulfate transport, nonste-roidal antiinflammatory drugs (rats), 750
targeting of 6-mercaptopurine (rats), 841
L-158,338, 1,2-hydride shift in microsomal metabolism (rats), 670L-69l,l2l, metabolism studies, class III antiarrhythmic agent (dogs), 467
Labetalol, disposition and metabolism, pharmacodynamics (sheep), 284(R),(R)-Labetalol, indolic metabolite (monkeys), 198Lactone, FK 506, oxidative metabolites (rats), 971Lipids, metabolic inversion of (R)-ibuprofen, formation, ibuprofenyl-
coenzyme A (rats, humans), 1 14Lipophilicity, hepatic dispersion and, homologous series of barbiturates,
liver (rats), 933
Lipopolysaccharide, bacterial, disposition and renal handling, endotox-
emia (rats), 611Liver
N-acetylation polymorphism (rats), 965arsenite effects, NAD(P)H:quinone acceptor oxidoreductase (rats), 334
aryl sulfotransferase IV, naphthaldehydes as reversible inhibitors (rats),
400
biotransformation
cocaine (guinea pigs), 390plasma clearance and, CQA 206-291 (humans, dogs, rats), 454proterguride (rats), 203
caffeine metabolism, postnatal development (rats), 178cholesterol sulfation (humans), 268clearance, colchicine-specific Fab fragments (rats), 997
CYP3A1 induction, modulation, polyinosinic acid-polycytidylic acid(rats), 520
disposition of morphine, 3- and 6-glucuronide metabolites (sheep),
1151
disturbances, propofol kinetics (rabbits), 7drug metabolism, Phases I and II, comparison (humans, monkeys),
753
effect of P-450 inducers, biiary excretion, glutathione and its hydrol-ysis products (rats), 342
elimination of ditekiren (rats), 184extra.hepatic metabolism and, salbutamol (rabbits), 485failure, pharmacokinetic properties, BM 06.022 (rats), 236flavin-containing monooxygenase, oxidation of desmethylprometha-
zinc (pigs), 24fluorine NMR studies, flumecinol metabolism (rats), 105
inhibition by ethanol, metabolism of cocaine, benzoylecgonine and
ecgonine methyl ester (mice, humans), 537in situ perfused, carbovir disposition (rats), 724lipophilicity and hepatic dispersion, homologous series of barbiturates
(rats), 933localization ofglutathione conjugation activities, bromosulfophthalein
(rats), 1070mitochondrial and cytosolic aldehyde dehydrogenases, inhibition by
crotonaldehyde (rats), 396morphine uptake, 3- and 6-glucuronidation (guinea pigs), 13nonprotein sulthydryl content, temporal effects, 1,1-dichloroethylene
(mice), 770pharmacokinetics, zidovudine bioavailabiity (mice), 189precision-cut slices
simple incubation system, metabolism studies (rats), 699
1182 SUBJECT INDEX
tolbutamide metabolism (rats, dogs), 705samples obtained as surgical waste, kinetic characterization, S-me-
phenytoin 4-hydroxylase (humans), 747
tirilazad disposition (rats), 951UDP-glucuronosyltransferases, substrate specificities, UGT1 gene fam-
ily, 50
Liver microsomesangiotensin II receptor antagonists, tetrazole N-glucuronidation (rats,
dogs, monkeys, humans), 792bioactivation and irreversible binding, tacrine (humans, rats), 874biotransformation of 5-chloro-3-phenylthioindole-2-carboxamide, po-
tent HIV-l reverse transcriptase inhibitor (monkeys, rats), 598
characterization, cytochrome P-450 2B6 (humans), 1048
cyclosporine metabolism (rats), 730cytochrome P-450, reductive metabolism, zonisamide (rats), 777cytochrome P-450-mediated dehydrogenation, 2-n-propyl-2(E)-pen-
tenoic acid (rats), 242enflurane defluorination, cytochrome P450 2El as major catalyst
(rats),350erythromycin-induced, isomerized epoxide metabolite, FK-506 (rab-
bits), 850fractions, CYP3A-mediated N-deethylation, amiodarone (humans),
978
$-glucuronidase-resistantglucuronide conjugate, digitoxin (dogs), 1147
glucuronidation of 3’-azido-3’-deoxythymidine, effect, anticancer
drugs (humans), 8231,2-hydride shift, metabolism of L-l 58,338 (rats), 670
hydroxylation ofdantrolene, cytochrome P-450 isozymes (rats), 9396�-hydroxylation oftestosterone, famiciclovir (humans), 18
inhibition by verapamil, enantioselective oxidative metabolism, me-
toprolol (humans), 309metabolism of 2,2-dichloro-l,l,1-thfluorethane (rats), 551metabolism of N,N-diethylbenzamide, N,N-diethyl-a,a’-’3C-benza-
mide(rats), 133
mixed function oxidase system, effects of clarithromycin (rats), 358NADPH and oxygen consumption, isoflurane-facilitated 2-chloro-l,l-
difluoroethene metabolism (rabbits), 299�9-naphthoflavone, verlukast metabolites, epoxide intermediate (rats,
mice), 861ortho chlorine substituents, metabolism of4-toluidines, 508
oxidation ofterfenadine (humans), 403oxidative metabolites of FK506 (rats), 971propranolol metabolism, regioselective contribution, cytochrome P-
450 2D subfamily (rats), 1012quantitation of butadiene metabolites (rats), 121stereo- and regioselective N- and S-oxidation, tertiary amines and
sulfides (humans), 492I digitoxigenin monodigitoxoside
(humans), 338
Lovastatin, biotransformation, species differences (mice, rats, dogs, hu-
mans), 1003
Lung
arsenite effects, NAD(P)H:quinone acceptor oxidoreductase (rats), 334doxorubicin uptake, influence, temperature and plasma protein (rab-
bits), 428metabolism of4-(methylthtrosamino)-1-(3-pyridyl)-l-butanone, inhib-
itory effects, NSAIDS (mice), 293nonprotein sulfhydryl content, temporal effects, l,l-dichloroethylene
(mice), 770LY2 17896, see 1,3,4-Thiadiazol-2-ylcyanamideLysobactin, chemical and enzymatic hydrolysis, application, immobi-
lized digestive enzyme assay, 573
Macrolide, lactone FK506, oxidative metabolites (rats), 971
N-Mandelyl-2-aminoethanol, oral [‘4C]cefcanel daloxate hydrochloridedisposition (humans), 171
Mass spectrometry, drug metabolism studies, “intrinsic” and “extrinsic”labels, midazolam (dogs), 868
Maturation, postnatal development, caffeine metabolism, liver slices(rats),178
Melphalan, reaction with water, phosphate and glutathione, kinetic
analysis (humans), 986S-Mephenytoin 4-hydroxylase, kinetic characterization of activity, liver
samples obtained as surgical waste (humans), 747Merbazone, differential metabolism, xanthine oxidase and microsomal
flavoenzymes (rats),410
6-Mercaptopurine, targeting to kidneys (rats), 841Metabolism studies, simple incubation system, precision-cut liver slices
(rats), 699Metalloporphyrins, water-soluble, oxidative drug metaboilsm studies,
model systems, 81 1Methamphetamine, self-administration by smoking, pharmacokinetics
(humans), 717
Methoxyresorufin, inducibility of enzyme activities, cytochrome P4501A family, �iepatocytes (human), 56
3-Methylcholanthrene, -induced liver, nonlinear elimination, xanthine-
related ethimizol (rats), 5474-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone
effect of tobacco smoke condensate on metabolism, adult and fetal
microsomes (hamsters), 318metabolism in lung explants, inhibitory effects, NSAIDS (mice), 293
lla-Methyltestosterone, biotransformation and branchial excretion
(fish), 377Metoprolol, enantioselective oxidative metabolism, inhibition by vera-
pamil, liver microsomes (humans), 309
Microbes, Cunninghamella elegans, formation of furosemide glucoside,259
Microsomes
adrenal, monooxygenase, zonal differences in thermal lability (guineapigs), 200
adult and fetal, effects of tobacco smoke condensate, 4-(methylnitro-samino)-l-(3-pyridyl)-l-butanone (hamsters), 318
Midazolam, drug metabolism studies, “intrinsic” and “extrinsic” labels
(dogs), 868
Mitochondria, hepatic, cytosolic aldehyde dehydrogenase and, inhibition
by crotonaldehyde (rats), 396Mitozolomide, orally administered, biodistribution and metabolism
(mice), 560
Mixed function oxidase system, effects ofclarithromycin, hepatic micro-somes (rats),358
Models, multicompartment, terminal disposition half-life, mean red-
dence time, 1172
Monooxygenases
adrenal microsomal, zonal differences, thermal lability (guinea pigs),
200flavin-containing
cytochromes P450 and, biotransformation of 4-fluoro-N-methylan-iline, 218
oxidation ofdesmethylpromethazine, liver (pigs), 24metabolic N-demethylation, l,3-bis[[l-cycloheptyl-3-(p-dimethylami-
nophenyl)ureido] methyljbenzene dihydrochloride (rats), 524stereo- and regioselective N- and S-oxidation, tertiary amines and
sulfides, liver microsomes (humans), 492Morphine
3- and 6-glucuronide metabolites, disposition, morphine infusion
(sheep), 1151uptake and 3- and 6-glucuronidation, stomach and intestine, colon
and liver (guinea pigs), 13
Multiple indicator dilution technique, localization of glutathione conju-gation activities, bromosulfophthalein (rats), 1070
Mycodysplasia, pharmacokinetics of 3-hydroxypyridin-4-ones (rabbits),
255
Myeloperoxidase, system, N-chlorination, sulfamethoxazole and dap-
sone, 830
SUBJECT INDEX 1183
NADPH, oxygen consumption and, isoflurane-facilitated 2-chloro-1,l-
difluoroethene metabolism, liver microsomes (rabbits), 299NAD(P)H:quinone acceptor oxidoreductase, effects ofarsemte, liver and
lung, heart and kidney (rats), 334Naphthaldehydes, reversible inhibitors, hepatic aryl sulfotransferase N
(rats), 400�-Naphthoflavone
arsenite effects, NAD(P)H:quinone acceptor oxidoreductase activity,various organs (rats), 334
verlukast metabolites, epoxide intermediate, hepatic microsomes (rats,
mice), 861
Nasal tissue, carboxylesterase-mediated metabolism, kinetics, vinyl ace-
tate(rats),1 107
Nefazodone, pharmacokinetics, bioavailability and disposition (dogs),
502Nephrotoxicity, cisplatin, reduction, sodium selenite (mice, rats), 30Nicotine glucuronide, rate ofexcretion in bile (rats), 927Nitecapone, identification of major metabolites (rats, dogs), 325Nitric oxide, nitrite ion not an active intermediate, vascular metabolism,
organic nitrates and organic nitrites, 967P�-Nitro-L-arginine, pharmacokinetics (rats), 962Nonsteroidal antiinflammatory drugs
inhibition of sulfate transport, kidney membrane vesicle preparations(rats),750
inhibitory effects, metabolism of 4-(methylnitrosamino)-l-(3-pyridyl)-
1-butanone, lung explants (mice), 293Nuclear magnetic resonance, fluorine, flumecinol metabolism (rats), 105
Obesity, nutritional, induction ofCYP2B enzymes, phenobarbital treat-
ment (rats),782
l,2,4-Oxadiazole, cleavage ofring, metabolism of SM-6586, 1167
Oxazepam, metabolism and elimination (mice), 918Oxygen
consumption and NADPH, isoflurane-facilitated 2-chloro-l,1-difluo-roethene metabolism, liver microsomes (rabbits), 299
oxidative drug metabolism studies, model systems, 811
Pafenolol, presystemic elimination, pharmacokinetics and metabolism(rats,humans), 435
Pamidronate, 4-hour and 24-hour infusions, clearance and tissue uptake(rats), 100
Pancreas, N-acetylation polymorphism (rats), 965Pazinaclone, stereoselective metabolites (dogs), 805Peroxidase-mediated metabolism ofcyclophosphamide (mice), 37Phencycidine, pharmacokinetics of phenylcyclohexyldiethylamine
(rats), 125Phenobarbital
acute administration, disposition ofacetaminophen metabolites (rats),1129
induction ofCYP2B enzymes, nutritional obesity (rats), 782Phenols, liver UDP-glucuronosyltransferases, substrate specificities,
UGT1 gene family, 50Phenylcyclohexyldiethylamine, pharmacokinetics (rats), 125
Phosphate, reaction ofmelphalan, kinetic analysis (humans), 986Phosphodiesters, 2’,3’-dideoxycytidine diphosphocholine, 2’,3’-dideox-
ycytidine diphosphoethanolamine, characterization, 738Placenta, no metabolism of 2’,3’-dideoxyinosine (humans), 544Plasma
clearance, biotransformation, CQA 206-291 (humans, dogs, rats), 454protein and temperature, doxorubicin uptake, lungs (rabbits), 428proteins, in vitro irreversible binding, ketoprofen glucuronide (rats),
617tirilazaddisposition (rats), 951
Plasminogen activator, BM 06.022, pharmacokinetic properties, influ-ence of hepatic and renal failure (rats), 236
Poisoning, acute, pharmacokinetic study, p-chloronitrobenzene (hu-mans), 1142
Polyethylene glycol, -derivatized proteins, strategy for characterization,911
Polyinosinic acid-polycytidylic acid, modulation, hepatic CYP3A1 in-
duction (rats), 520Pregnancy
hepatic biotransformation ofcocaine (guinea pigs), 390
maternal/fetal plasma concentrations of cocaine, transplacental phar-macokinetics (monkeys), 364
Progesterone, caffeine and estradiol, interaction with CYP1A1 andCYP1A2, Saccharom�es cerevisiae (human), 43
Propofol, kinetics, effect of cimetidine, inflammation and hypoxia (rab-
bits), 7Propranolol
disposition and negative dromotropic activity, diltiazem, multiple
dosing (dogs), 156metabolism in liver microsomes, regioselective contribution, cyto-
chrome P450 2D subfamily (rats), 1012Propylene glycol, disposition of Dramamine (rabbits), 3052-n-Propyl-2(E)-pentenoic acid, cytochrome P-450-mediated dehydro-
genation, liver microsomes (rats), 242
Prostaglandin H synthase, peroxidase-mediated metabolism, cyclophos-phamide (mice), 37
Proteases, digestive, degradation oflysobactin, 573Proteins, polyethylene glycol-derivatized, strategy for characterization,
911Proterguride, biotransformation in liver (rats), 203
Protoporphyrin-cobalt and cobalt chloride, pharmacokinetics (rats), 846
Pseudohexapeptide, ream inhibitor, hepatic elimination, ditekiren (rats),
184
Ractopamine hydrochloride, metabolism and disposition (turkeys), 624Receptors
angiotensin IIantagonists, tetrazole N-glucurothdation in hepatic microsomes
(rats, dogs, monkeys, humans), 792nonpeptide antagonist L-158,338, 1,2-hydride shift in microsomal
metabolism (rats), 6705-HT3, antagonist zatosetron (humans), 249
Red blood cellsinhibition ofN-acetyltransferase (humans), 181role ofbinding in hepatic clearance, disposition of tacrolimus (rabbits),
690
Refrigerants, biotransformation of halothane, concentration-dependentinhibition (guinea pigs), 386
Renin, inhibitor pseudohexapeptide, ditekiren, hepatic elimination (rats),184
Risperidone, absorption and metabolism, excretion (humans), 1134RNA, messenger, head injury and cytochrome P450 enzymes (rats),
1064DL-Rolipram, biotransformation, metabolites from wine (rats, monkeys,
humans), 682
Saccharomyces cerevisiae, cDNA-directed expression, interaction with
CYP1A1 and CYP1A2, caffeine/estradiol/progesterone (human),43
Salbutamol, hepatic and extrahepatic metabolism (rabbits), 485Salicylazosulfapyridine, its metabolites and, toxicokinetics (mice), 1091Salmeterol xinafoate, disposition (rats, humans), 1022Sanguinarmne, biometabolic elimination, organ retention profile (rats,
guinea pigs), 194L-734,005, see 5-Chloro-3-phenylthioindole-2-carboxamide
Sematilide, comparative kinetics (rats, rabbits, dogs, humans), 662Sevoflurane, metabolism, inhibitory effects, deuteurium substitution
(rats), 1170Sex differences, tolbutamide metabolism, precision-cut liver slices (rats,
dogs), 705Sex hormone-dependent cytochrome P450, sulfamethazine as a model
compound (rats), 441SM-6586, metabolism, cleavage, 1,2,4-oxadiazole ring, 1167
Sodium selenite, reduction of cisplatin nephrotoxicity (mice, rats), 30
1184 SUBJECT INDEX
Species differences, biotransformation of lovastatin (mice, rats, dogs,
humans), 1003Spironolactone, metabolites in plasma and target organs (guinea pigs),
1086Stomach, morphine uptake, 3- and 6-glucuronidation (guinea pigs), 13
Substrates, oxidative drug metabolism studies, model systems, 811Sulfamethazine, model compound, sex hormone-dependent cytochrome
P450 activity (rats), 441
Sulfamethoxazole, dapsone and, N-chlorination, myeloperoxidase sys-tem, 830
Sulfasalazine, its metabolites and, toxicokinetics (mice), 1091
Sulfate, inhibition of transport, kidney membrane vesicle preparations,nonsteroidal antiinflammatory drugs (rats), 750
Sulihydryl, nonprotein content of lung and liver, temporal effects, 1,1-dichloroethylene (mice), 770
Sulindac, inhibitory effects on carcinogen metabolism, lung explants
(mice), 293Sumatriptan, disposition (rats, mice, dogs, rabbits, humans), 761
Tacrine, bioactivation and irreversible binding, liver microsomes (hu-mans, rats), 874
Tacrolimus, see FK 506Tamoxifen
metabolism, cytochrome P450-catalyzed N-demethylation, 4-hydrox-
ylation (rats),645, 657
phase I and phase II metabolites, breast cancer (humans), 1119T-cdlls, anomalous accumulation and decay, 2’,3’-dideoxyadenosine-5’-
triphosphate, 2’,3’-dideoxyinosine exposure (humans), 369Temperature, plasma protein and, doxorubicin uptake, lungs (rabbits),
428Terfenadine, oxidation in liver microsomes (humans), 403
Testicles, spironolactone metabolites, plasma and target organs (guineapigs),1086
Testosterone
6fi-hydroxylation, famiciclovir, liver microsomes (humans), 18pharmacokinetics ofzenarestat, diabetes (rats), 677
Tetrazole, N-glururonidation, angiotensin II receptorantagonists, hepaticmicrosomes (rats, dogs, monkeys, humans), 792
Thalassemia, intravenous infusion pharmacokinetics, desferrioxamine
(humans), 640$-Thalassemia, pharmacokinetics of 3-hydroxypyridin-4-ones (rabbits),
255l,3,4-Thiadiazol-2-ylcyanamide, biotransformation, characteristics, me-
soionic ribose metabolite (mice), 162
Thiazolulbenzimidazole, metabolism and disposition, activity against
ThiolHIV-1 (mice), 231
carbamoylate conjugates, metabolites of 142-chloroethyl)-3-cycloh-exyl-l-nitrosourea (rats, humans), 889
conjugates of reactive metabolites, 4-ene VPA and 4-pentenoic acid,
1098Thromboxane synthase, inhibitor 5,6-dihydro-7-(lH-imidazol-1-yl)-
naphthalene-2-carboxylic acid, in vivo glucuronidation (rats, hu-mans), 151
Tirilazad, disposition, plasma and heart, brain and liver (rats), 951
Tobacco smoke condensate, metabolism of 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone, adult and fetal microsomes (hamsters), 318
Tolbutamide, metabolism in precision-cut liver slices, qualitative andquantitative sex differences (rats, dogs), 705
4-Toluidines, microsomal metabolism, ortho chlorine substituents, 5083-Trifluoromethyl-a-ethylbenzhydrol, see FlumecinolTyrosine-ester sulfotransferase, naphthaldehydes as reversible inhibitors,
hepatic aryl sulfotransferase IV (rats), 400
502U83, DNA intercalator, pharmacokinetics and disposition (rats), 62U71038, see DitekirenU74006F, see Tirilazad
UDP-glucuronsyltransferaseactivity toward digitoxigenin monodigitoxoside, liver microsomes(hu-
mans), 338liver, substrate specificities, UGT1 gene family, 50
Urinemetabolites, biotransformation of DL-rolipram (rats, monkeys, hu-
mans), 682metabolites ofbiantrazole, detection and identification (humans), 955
Valproic acid4-ene VPA and 4-pentenoic acid, reactive metabolites, thiol conjugates,
10982-n-propyl-2(E)-pentenoic acid, cytochrome P450-mediated dehydro-
genation, liver microsomes (rats), 242�9-oxidation, stereochemical studies, hepatocytes (rats), 580
Vanadate, oral treatment, pretranslational induction, CYP4A subfamily
gene products (rats),745Velnacrmne maleate, disposition (rats, dogs, humans), 1037
Verapamil, inhibition, enantioselective oxidative metabolism of meto-
prolol, liver microsomes (humans), 309Verlukast
epoxidation, CYP1A1 specificity (mice, rats, monkeys, humans), 1029metabolites arising from an epoxide intermediate, �9-naphthoflavone,
hepatic microsomes (rats, mice), 861Vigabatrin, pharmacokinetics and metabolism (humans), 480Vinyl acetate, carboxylesterase-mediated metabolism, kinetics (rats),
1107
Water, reaction of melphalan, kinetic analysis (humans), 986
Xanthine-related drug ethimizol, nonlinear elimination, 3-methylchol-anthrene-induced liver (rats), 547
Xanthine oxidase, microsomal flavoenzymes and, differential metabo-lism, merbazone (rats), 410
XenobioticsCYP1A1 specificity, verlukast epoxidation (mice, rats, monkeys, hu-
mans), 1029metabolic inversion of (R)-ibuprofen, formation, ibuprofenyl-coen-
zyme A (rats, humans), 114
Zatosetron, disposition (humans), 249Zenarestat, pharmacokinetics, diabetes (rats), 677Zidovudine, bioavailability and liver pharmacokinetics (mice), 189
Zonisamide, reductive metabolism, liver microsomal cytochrome P450(rats), 777
Zopiclone, its enantiomers and, pharmacokinetics (humans), 1125
Copyright © 1993 by The American Society for Pharmacologyand Experimental Therapeutics
L�LI)
The top ranking journal in the field...
PharmacologicalA Publication ofthe American Society for
Pharmacology and Experimental Therapeutics, Inc.
Robert E. Stitzel, PhD, EditorWest Virginia University Medical Center
P harmacological Reviews is a show-case
for importantreview articles in your field,
featuring more comprehensive papers on topics
of high current interest.
The Journal continues to publish the important,
longer papers of interest to pharmacologists,
physiologists, toxicologists, and biological
chemists. No library serving the pharmacologist
should be without a subscription.
Published Quarterly
Discounts available to members on all
ASPET publications.Save 10% when ordering two
Save 15% when ordering three
Save 20% when ordering four
#{149}:#{149}
I Please enter my subscription to Pharmacological Reviews. Payment Options: (��) II �:i Check enclosed (payable to Williams & Wilkins)
I � Individual $60/year J Bill me �J American Express � MasterCard � VISAI �:i Institutional $107/year Card # Exp. date ______I �i In�training* $45/year Signature or P.O. # ___________________________ ___________ II (add $15/year outside the U.S.; in Canada also add 7% GST) MD and PA subscribers must add state sales tax. Subscriptions outside II � New Subscription �1 Renewal the U.S. must be prepaid in U.S. dollars. In Japan, contact Igaku-Shoin.
: Subscribe for: El 3 years �J 2 years 1 1 year MYW. Ltd. (03) 5689-5400. Rates valid through October 31, 1994.I Return coupon to:
IName ____________________ .. .
I Address ____________________________________________________ Williams & WllklnsI . . A WAVERLY COMPANY
City/StateP� #{149} #{149}. P.O. Box 23291. Baltimore, MD 21203-9990
I * Please indicate institution/statusI For credit card orders, call TOLL FREE:I 1-800-638-6423 in the U.S. or Canada.
L__vrs 55077 Printed n (iSA J4077S ZPT�,,J
voL�pJ(: 4.�4CM#{216}�f1
.:ijp4�
A WAVERLY COMPANYMOL 55049 Printed in USA J4049S ZMOL
MOLECULARPHARM
Editor: T. Kendall Harden, PhD, University of North CarolinaSchool of Medicine, Chapel Hill, North Carolina
Is �‘our special interest receptors and neurotransmitters . . . drugmetabolism . . . antibiotic and anticancer drug actions . . . or otherareas related to the molecular basis ofdrug action? Ifso, youshould he subscribing to MOLECULAR PHARMACOLOGY.
The editor’s and editorial board’s high standards ensure that thepapers you read in MOLECULAR PHARMACOLOGY are on thecutting edge ofresearch on drug action and selective toxicity at themolecular level. Original applications of biochemistry, biophysics,genetics, and molecular biology arejuxtaposed with innovativepharmacologic research to elucidate basic problems in pharma-cologv and toxicology, including such areas as molecular mecha-nisms involved in drug receptor-effector coupling, xenobioticmetabolism, and antibiotic and anticancer drug action. Start yoursubscription today to ensure access to the most newsworthy papersinyour field. Month lv
Call toll-free to start your subscription immediately, 1-800-638-6423fromanywhere in the ITS. or Canada.
r - - - - - - - - - - - - - - - - - - - - - - � � - - - -
Avoid luture rate increases ar�l ensure uninterruptcd scr’.i�e--enter Payment options.�our niultivear SLII)sTiption today E Chek eii�1osed � Bill �e
E \ISA E �lasterCard E Anieri�an Express
Molecular Phannacol�gy ( ili)ntlllv)� lnli�k1ua1: $ LOS yr � Institutions: �23O �i �ar�j �
(I�Iea.�e (k/(/S�)’UO() ()l1t.cl�/’ the ( IS. in (��,icic1a. alco aiki ‘� GST __________________________________________________________________________________E N(.�\v � E Rene��:d E 3 ‘is E 2 \rs E 1 � �igiiat�irc P 0
MD and PA subscribers must add state sales tax. Subscriptions from outside the IJSand Canada must be prepaid. in US dollars o,t/v. In Japan. contact Igaku-Shoin
MYW Ltd. (03) 5689-54(X). Rates valtd for orders received through October 31.
11.It1k� l9�)4.
________________________________________________________________________________________Please allow S v’ceks tor delivers 0) your first issue. Surface mail dcliser� to
.iddrcs� countries outside the LTS nia� take up to 1(� ssecks. Airmail rates available upon
request.
� its ��t.itt#{149}/1)) Discounts available to members on all ASPET publications. SAVE � a henordering t\’O. SAVE 1�( when ordering three. SAVE 2U�? when ordering all tour.
\\,T jjj . �:�: � jJ�j i o Box 2�2�) 1 Rn �tJ�x .tv H& USC
B.IItit�()re. �sIjr land .� 1.�i3 9Q�5) 2U I�i1hant Broaj��asL&iiidoii �\‘i�#{149}(�� IA.A Eng1at�i